Compiled by Cari Kraft, Jacobs Management Group, Inc.


Social media is outperforming TV

Google sites are attracting monthly audiences of 247 million people, nearly 10% better than the 228 million of the #1 network’s primetime shows. Facebook, Yahoo and Microsoft sites are also doing as well or better than the other three major networks.

Source: comScore Xmedia (Live TV, 8 PM-11 PM) and Media Metrix Multi-Platform, U.S., November 2015



Revenue from one drug

Evaluate Pharma predicts the Pharmaceutical Market to be over 1.2 Trillion by 2022. They predict the biggest-selling global branded drug will be Opdivo (nivolumab) from BMS and Ono Pharma, with sales projected to go from $1.119 billion in 2015 to $14,634 billion, and overtaking the current No. 1 drug, AbbVie’s and Eisai’s Humira (adalimumab), currently at $14.359 billion and dropping slightly to $13.645 billion in 2022.

Source: “World Pharma Preview 2016, Outlook to 2022”, Evaluate Pharma, September 2016

Medical Device Clearances Decreasing

The number of medical device submissions cleared by the FDA declined significantly in 2015, to 3025 from a high of 3203 in 2014. It didn’t reach the levels of 2011 (3126), 2012 (3138) or even a relatively low figure from 2013 (3054).

Source: “Emergo Analysis: Fewer 510(k) Submissions from US Medical Device Firms in 2015”, Emergo, February 2016




R&D Spending as a percentage of sales

Total R&D as a percentage of total sales was 19.8% in 2015. Domestic R&D as a percentage of domestic sales was even higher at 24.8%.

Source:“2016 Biopharmaceutical Research Industry Profile”, Pharmaceutical Research and Manufactures of America, April 2016


Total revenue of the top 100 healthcare companies in 2015

All sectors—pharmaceutical, bio and device—increased in revenue over 2014, bringing revenue higher than it’s ever been.

Source: “Top 100 Healthcare Companies”, Healthcare Sales & Marketing Magazine, September/October 2016



U.S. pharmaceutical stock returns top other industries

U.S. pharmaceutical companies dominated an annual global ranking of top 10 large-cap stocks with the best five-year returns. This was skewed somewhat by some of the largest companies. Drug company Regeneron Pharmaceuticals, which had an average annual total share return of 75.3 per cent, was the top performer. Allergan and Gilead Sciences, with 43.3 per cent and 41.4 per cent average annual returns, respectively, took second and third place. Companies with over US$4 billion in market cap were considered for the list and ranked based on share gains and dividend yields between 2011 and 2015. Some 2,000 stocks were analyzed.

Source: BCG Perspectives, Boston Consulting Group, May 2016



Biopharma industry accounts for 21% of all U.S. R&D

Members of the Pharmaceutical Research and Manufacturers of America (PhRMA) invested a combined $58.8 billion in research and development during 2015, up from $53.3 billion the previous year. The second-highest industry, software, accounted for 11% of R&D spending.

Source: “2016 Biopharmaceutical Research Industry Profile”, Pharmaceutical Research and Manufactures of America, April 2016